Opinion|Videos|February 11, 2025
Potential Impact of Afami-Cel Therapy on the Standard of Care for R/R Cases
A panelist discusses how afamitresgene autoleucel (afami-cel) therapy could potentially transform the treatment landscape for relapsed/refractory (R/R) synovial sarcoma by offering a targeted cellular therapy option with demonstrated efficacy in heavily pretreated patients, though its optimal positioning in the treatment sequence will need to be determined through additional clinical experience and data.
Advertisement
Episodes in this series
Video content above is prompted by the following:
How might afami-cel therapy change the current standard of care for R/R cases?
Advertisement
Related to this article
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
5